Friday, Aug 07, 2020 | Last Update : 04:03 PM IST

136th Day Of Lockdown

Maharashtra47977931637516792 Tamil Nadu2791442210874571 Andhra Pradesh1967891128701753 Karnataka158254802812897 Delhi1415311271244059 Uttar Pradesh108974634021918 West Bengal86754610231902 Telangana7525753239601 Gujarat65704485612529 Bihar6203140760349 Assam4816233429115 Rajasthan4667932832732 Haryana3779631226448 Odisha3768124483258 Madhya Pradesh3508225414912 Kerala279561629988 Jammu and Kashmir2239614856417 Punjab1901512491462 Jharkhand140705199129 Chhatisgarh10109761369 Uttarakhand8008484795 Goa7075511460 Tripura5520367528 Puducherry4147253758 Manipur301818147 Himachal Pradesh2879171013 Nagaland24056594 Arunachal Pradesh179011053 Chandigarh120671520 Meghalaya9173305 Sikkim7832971 Mizoram5022820
  Science   03 Jul 2020  Zydus Cadila's potential covid drug may begin human clinical trials

Zydus Cadila's potential covid drug may begin human clinical trials

PTI
Published : Jul 3, 2020, 11:01 am IST
Updated : Jul 3, 2020, 11:01 am IST

India’s 'first' indigenous COVID-19 vaccine candidate Covaxin had also got the nod for human clinical trials recently

 Representational Image. (AP)
  Representational Image. (AP)

New Delhi: A potential COVID-19 vaccine indigenously developed by the Ahmedabad-based Zydus Cadila Healthcare Ltd has got the nod from the Drugs Controller General of India (DCGI) for human clinical trials, according to a government source.

The approval process was fast-tracked following a recommendation by the subject expert committee on COVID-19, considering the emergency and unmet medical need during the pandemic.

 

"DCGI Dr V G Somani has given approval for the phase I and II clinical trials (on humans) of the potential novel coronavirus vaccine developed by Zydus Cadila Healthcare Ltd on Thursday after its animal studies were found to be successful," an official source in the know of the developments told PTI.

The assent for human trials was given after the company submitted data of clinical trial on animals to the DCGI, in which the vaccine candidate was found to be successful with respect to safety and immunogenicity, the source said.

The company is likely to start enrolment of subjects soon.

"The phase I and II trials will take around three months to be completed," the source said.

 

The country's 'first' indigenous COVID-19 vaccine candidate Covaxin, developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research and National Institute of Virology (NIV), had recently got the nod for human clinical trials from the DCGI.

India's COVID-19 tally rose to 6,04,641 on Thursday with a single-day increase of 19,148 cases, just five days after it crossed the five-lakh mark, while the death toll rose to 17,834 with 434 new fatalities, according to the Union Health Ministry.

Tags: covaxin, hyderabad, bharat biotech, zydus cadila healthcare ltd, ahmedabad, drugs controller general of india (dcgi), human trial, covid-19 vaccine, coronavirus, indian vaccine
Location: India, Delhi, New Delhi